ResMed (RMD) Competitors $271.93 +1.79 (+0.66%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RMD vs. MEDP, EHC, HIMS, BSX, SYK, MDT, BDX, IDXX, EW, and DXCMShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), and DexCom (DXCM). These companies are all part of the "medical" sector. ResMed vs. Its Competitors Medpace Encompass Health Hims & Hers Health Boston Scientific Stryker Medtronic Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences DexCom ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Does the media prefer RMD or MEDP? In the previous week, Medpace had 5 more articles in the media than ResMed. MarketBeat recorded 23 mentions for Medpace and 18 mentions for ResMed. ResMed's average media sentiment score of 1.50 beat Medpace's score of 1.30 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 14 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, RMD or MEDP? ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResMed$5.15B7.74$1.40B$9.5128.59Medpace$2.11B6.54$404.39M$13.4536.49 Which has more volatility & risk, RMD or MEDP? ResMed has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Is RMD or MEDP more profitable? ResMed has a net margin of 27.22% compared to Medpace's net margin of 18.74%. Medpace's return on equity of 67.66% beat ResMed's return on equity.Company Net Margins Return on Equity Return on Assets ResMed27.22% 25.62% 18.69% Medpace 18.74%67.66%21.86% Do analysts rate RMD or MEDP? ResMed presently has a consensus price target of $278.36, suggesting a potential upside of 2.37%. Medpace has a consensus price target of $422.27, suggesting a potential downside of 13.97%. Given ResMed's stronger consensus rating and higher probable upside, research analysts plainly believe ResMed is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ResMed 1 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.82Medpace 3 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.94 Do institutionals & insiders hold more shares of RMD or MEDP? 55.0% of ResMed shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryResMed beats Medpace on 9 of the 17 factors compared between the two stocks. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$39.81B$10.53B$5.72B$21.51BDividend Yield0.87%1.88%5.73%3.49%P/E Ratio28.5921.0775.3229.84Price / Sales7.7430.27457.8652.74Price / Cash24.1125.0025.8118.13Price / Book6.683.5013.294.66Net Income$1.40B$210.63M$3.29B$999.94M7 Day Performance-2.67%-0.56%0.71%0.92%1 Month Performance-4.53%1.85%4.57%4.68%1 Year Performance9.24%-11.16%73.81%16.76% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed4.61 of 5 stars$271.93+0.7%$278.36+2.4%+8.7%$39.81B$5.15B28.5910,600Positive NewsMEDPMedpace4.3189 of 5 stars$492.09+1.0%$412.73-16.1%+39.5%$13.82B$2.11B36.595,900Positive NewsEHCEncompass Health4.7112 of 5 stars$125.93+0.3%$134.00+6.4%+35.2%$12.68B$5.37B24.6440,000Positive NewsShort Interest ↑HIMSHims & Hers Health2.4796 of 5 stars$49.77+2.8%$38.92-21.8%+234.8%$11.25B$1.48B62.211,637Analyst ForecastBSXBoston Scientific4.7828 of 5 stars$108.14+0.9%$117.79+8.9%+23.3%$160.23B$16.75B64.3753,000Positive NewsSYKStryker4.9353 of 5 stars$393.12+0.2%$430.10+9.4%+3.5%$150.29B$22.60B52.0753,000Positive NewsMDTMedtronic4.955 of 5 stars$92.91+0.0%$102.14+9.9%+4.5%$119.17B$33.54B25.5995,000Positive NewsBDXBecton, Dickinson and Company4.9536 of 5 stars$191.50-0.5%$211.44+10.4%-20.1%$54.89B$20.18B34.4474,000News CoveragePositive NewsIDXXIDEXX Laboratories4.2264 of 5 stars$652.83+1.5%$649.44-0.5%+28.1%$52.23B$3.90B54.3611,000Positive NewsEWEdwards Lifesciences4.6902 of 5 stars$80.28-0.8%$85.90+7.0%+13.1%$47.13B$5.44B11.5515,800News CoveragePositive NewsAnalyst DowngradeShort Interest ↑DXCMDexCom4.9782 of 5 stars$78.00-3.1%$99.89+28.1%+9.7%$30.59B$4.03B54.1710,300Positive News Related Companies and Tools Related Companies Medpace Competitors Encompass Health Competitors Hims & Hers Health Competitors Boston Scientific Competitors Stryker Competitors Medtronic Competitors Becton, Dickinson and Company Competitors IDEXX Laboratories Competitors Edwards Lifesciences Competitors DexCom Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RMD) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RMD Stock Alerts